NEUCHATEL, SWITZERLAND--(Marketwired - Oct 10, 2014) - Masimo (NASDAQ: MASI), maker of breakthrough Masimo SET ® Measure-through Motion and Low Perfusion™ Pulse Oximetry, today announced the CE Mark ...

Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse CO-Oximeter ®. Eve combines the power of ...

Masimo Corporation (NASDAQ:MASI) received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering ...

Masimo Corporation MASI received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering improved ...

Smaller, Flexible Sensors Are More Comfortable for Patients, Easier to Apply for Clinicians "Masimo's new low-profile sensors are not only flatter and easier to apply, but the added pliability allows ...

ZURICH, SWITZERLAND and IRVINE, CA--(Marketwired - Nov 22, 2013) - Masimo (NASDAQ: MASI) announced today that ACUTRONIC Medical Systems AG has integrated Masimo SET ® Measure-through Motion and Low ...

In 2016, Saudi Arabia implemented a mandatory CCHD screening program for all newborns using the Masimo Eve™ Newborn Screening Application on Radical-7 ® Pulse CO-Oximeters ® with SET ® Measure-through ...

Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...